Señales en vivo de RNAZ | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 abr 2024 @ 15:58):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
Volumen de hoy	1.11M
Volumen promedio	509 146
Capitalización de mercado	3.86M
EPS	$0 ( 2024-03-29 )
Próxima fecha de ganancias	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00200 (0.34%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

Volumen Correlación

Largo: 0.35 (neutral)

Corto: 0.49 (neutral)

Signal:(37.238) Neutral

TransCode Therapeutics, Correlación

10 Correlaciones Más Positivas
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 Correlaciones Más Negativas
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TransCode Therapeutics, Correlación - Moneda/Commodity

0.51
( weak )

0.00
( neutral )

0.57
( weak )

-0.85
( strong negative )

-0.32
( neutral )

TransCode Therapeutics, Finanzas

Annual	2023
Ingresos:	$0
Beneficio Bruto:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2023
Ingresos:	$0
Beneficio Bruto:	$-516 746 (0.00 %)
EPS:	$-103.61

FY	2022
Ingresos:	$0
Beneficio Bruto:	$-98 606.00 (0.00 %)
EPS:	$-2 165.71

FY	2021
Ingresos:	$0.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.133

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.